ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
At ESMO '26, Moderna and Merck's cancer vaccine intismeran showed a 42% reduction in melanoma recurrence risk, but Moderna's stock fell. Roche's divarasib outperformed competitors in KRAS-mutated lung cancer. Amgen's Imdelltra combo therapy reduced lung cancer death risk by 58%.
How this was made
The 30-second read
Why it matters
New Phase 3 data for Roche and Amgen are likely to drive upside, while Moderna and Merck face short‑term downside due to sell‑the‑news dynamics.
Market read
First‑report trial data for major oncology players, with immediate price impact and sector‑wide implications.
What to watch
Manufacturing scalability and regulatory pathways for patient‑specific vaccines could be longer‑term catalysts not reflected in the immediate price move.
Background
The article summarizes three major oncology trial updates presented at the ESMU 2026 meeting, highlighting both positive and negative outcomes.
Ticker impact
Moderna's melanoma vaccine trial data caused its shares to plunge double digits after the results were released.
downward pressure as market prices in the mixed trial outcome.
The data fell short of expectations and triggered a sell‑the‑news reaction.
Merck co‑developed the melanoma vaccine and saw its stock fall alongside Moderna after the ESMO data release.
downward pressure as investors weigh the limited applicability of the vaccine.
Joint trial results were below market hopes, prompting a sell‑the‑news move.
Amgen's Imdelltra plus Imfinzi combo cut death risk by 58% in small‑cell lung cancer, driving strong investor enthusiasm.
upward pressure as the combination may expand the drug's market and sales outlook.
The unprecedented survival benefit positions the therapy as a new standard of care.
Market effects
Positive data for Roche and Amgen may lift the broader oncology biotech sector, while Moderna/Merck setbacks could weigh on vaccine developers.
European biotech stocks may see mixed reactions; US biotech peers could be influenced by the same data.
High relevance for global investors tracking oncology pipeline breakthroughs.
Counterpoint
Moderna's valuation may still be justified if the vaccine succeeds in other tumor types, suggesting a potential rebound.
Key entities
- companyModerna
Biotech firm developing a melanoma vaccine.
- companyMerck & Co.
Partner in the melanoma vaccine trial.
- companyRoche
Developer of the KRAS inhibitor divarasib.
- companyAmgen
Producer of Imdelltra, now combined with Imfinzi.
